Market closedNon-fractional
aTyr Pharma/ATYR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Ticker
ATYR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
58
Website
www.atyrpharma.com
aTyr Pharma Metrics
BasicAdvanced
$154M
Market cap
-
P/E ratio
-$0.90
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$154M
Beta
1.19
Financial strength
Current ratio
6.065
Quick ratio
5.443
Long term debt to equity
15.413
Total debt to equity
16.76
Management effectiveness
Return on assets (TTM)
-29.37%
Return on equity (TTM)
-55.61%
Valuation
Price to revenue (TTM)
226.235
Price to book
1.8
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
-2.294
Growth
Revenue change (TTM)
-94.34%
Earnings per share change (TTM)
-36.49%
3-year revenue growth (CAGR)
-37.34%
3-year earnings per share growth (CAGR)
-26.66%
What the Analysts think about aTyr Pharma
Analyst Ratings
Majority rating from 5 analysts.
aTyr Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$200K
∞%
Net income
-$15M
4.76%
Profit margin
-7,700.00%
-∞%
aTyr Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.20
-$0.25
-$0.23
-
Expected
-$0.28
-$0.23
-$0.24
-$0.24
-$0.24
Surprise
-21.03%
-11.50%
5.04%
-2.54%
-
aTyr Pharma News
AllArticlesVideos
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
GlobeNewsWire·2 months ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for aTyr Pharma stock?
aTyr Pharma (ATYR) has a market cap of $154M as of July 27, 2024.
What is the P/E ratio for aTyr Pharma stock?
The price to earnings (P/E) ratio for aTyr Pharma (ATYR) stock is 0 as of July 27, 2024.
Does aTyr Pharma stock pay dividends?
No, aTyr Pharma (ATYR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next aTyr Pharma dividend payment date?
aTyr Pharma (ATYR) stock does not pay dividends to its shareholders.
What is the beta indicator for aTyr Pharma?
aTyr Pharma (ATYR) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell aTyr Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.